Chris Yates 

Chris is an accomplished medicinal chemistry and scientific leader with over 20 years of experience in the pharmaceutical and biotech industry. Before joining Rgenta to focus on target RNA with small molecules, he was at Kymera Therapeutics, a leader in targeted protein degradation, engaged in leading both internal and collaboration efforts focused on novel E3 ligase exploration and novel protein target degradation and validation. Prior to moving to the Boston area, Chris lived in North Carolina where he worked at both Viamet Pharmaceuticals and GlaxoSmithKline. 

During his time in industry, Chris has directed activities across all stages of drug discovery in multiple therapeutic areas and small molecule modalities contributing to over 50 publications and patents, multiple development candidates, 3 INDs, and 1 marketed drug, VIVJOA® (oteseconazole).